


## HIF-1 inhibitor-4

<b>Cat. No.:</b>	HY-153017		
<b>CAS No.:</b>	333357-56-5		
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>19</sub> IN <sub>2</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	422.26		
<b>Target:</b>	HIF/HIF Prolyl-Hydroxylase		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 25 mg/mL (59.21 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.3682 mL	11.8410 mL	23.6821 mL
5 mM	0.4736 mL	2.3682 mL	4.7364 mL
10 mM	0.2368 mL	1.1841 mL	2.3682 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 1.11 mg/mL (2.63 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 1.11 mg/mL (2.63 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

HIF-1 inhibitor-4 is a HIF-1 inhibitor (IC<sub>50</sub>: 560 nM). HIF-1 inhibitor-4 reduces the HIF-1α protein level without affecting its mRNA level<sup>[1]</sup>.

#### In Vitro

HIF-1 inhibitor-4 (Compound 1) inhibits HIF-1 with an IC<sub>50</sub> of 560 nM, quantified using U251 cell expressing a PLAP reporter gene under the control of a VEGF promoter (VEGF-PLAP)<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

---

[1]. Nagao S, et al. Synthesis and structure-activity relationships of novel, potent, orally active hypoxia-inducible factor-1 inhibitors. *Bioorg Med Chem*. 2014 Oct 1;22(19):5513-29.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA